GLP-1 coverage without the PBM: a smarter model for employers

For most self-funded employers, GLP-1 coverage means one thing: a conversation with your pharmacy benefit manager. The PBM negotiates net drug pricing, manages prior authorization, handles formulary placement. And it provides quarterly reports showing how much your plan is spending on semaglutide and tirzepatide — numbers that, for most employers, have been rising sharply every year since 2022.

What the PBM model actually delivers

The PBM model creates specific problems for GLP-1 coverage. Rebate opacity makes net GLP-1 prices difficult to verify independently until renewal. Prior authorization without care management confirms clinical criteria but doesn’t ensure behavioral support or a trajectory toward reduced medication use. There is no tapering mechanism — employees remain on medication at their prescribed dose indefinitely. And the high-dose default means most PBM-managed utilizers are on or approaching 2.4 mg/week regardless of whether a lower dose would achieve equivalent outcomes.

The alternative: a clinically managed carve-out

The model emerging as the most compelling alternative for mid-market employers is a specialty carve-out — a clinically managed GLP-1 program that operates outside the medical plan and PBM, designed from first principles around outcomes rather than drug access.

The defining characteristics: treat-to-target dosing (Embla’s real-world average is 1.08 mg/week, one-third the standard maximum); behavioral care as the foundation rather than the supplement; a built-in tapering protocol (78.5% taper success in the TRIM study); no plan integration required; and pay-per-engaged-member pricing.

What brokers need to know

The differentiation story is clinical, not just administrative. The value of recommending a carve-out like Embla is 16.7% average weight loss and 78.5% taper rate, published in peer-reviewed literature — a differentiator a broker can bring to a CFO conversation, not just HR. It also creates a documented, defensible employer GLP-1 policy, which has legal value as ADA and EEOC guidance on obesity continues to evolve.

When PBM-integrated coverage still makes sense

A carve-out isn’t the right answer for every employer. Large employers with dedicated pharmacy benefit resources and active PBM rebate optimization may find plan-integrated coverage a better fit. Employees with type 2 diabetes may be better served through integrated coverage. And for employers who have already embedded GLP-1 coverage deeply in their plan design, adding a carve-out as a complementary option is often the most practical path.

Bottom line

The PBM-managed GLP-1 benefit is the default — not because it produces the best outcomes, but because it’s the path of least resistance. A clinically managed carve-out requires finding a vendor with genuine clinical differentiation, real-world evidence, and a business model aligned with reducing drug dependence rather than perpetuating it. For self-funded employers who want GLP-1 coverage they can defend clinically, financially, and structurally — the conversation about going outside the PBM is worth having.

Embla operates as a fully managed carve-out — no PBM, no plan integration, live in 7 days. Talk to our team →